ProFound Gets Up to $35M for Preeclampsia Discovery

ProFound Therapeutics has received an investment commitment of up to $35M from the Gates Foundation, including an initial $20M investment. The Cambridge-area biotechnology company will use the capital to search the expanded human proteome for biomarkers, protein drugs, and drug targets connected to preeclampsia and eclampsia.

The announcement is not a conventional venture round with a disclosed valuation or ownership stake. It is a disease-specific research commitment with a defined scientific job: analyze proteins expressed in placental and serum samples, test how those proteins connect to disease biology, and build a preeclampsia- and eclampsia-specific AI tool.

That work sits inside a larger maternal-health problem. The World Health Organization estimates that preeclampsia affects 3%-8% of women who give birth worldwide, and hypertensive disorders caused about 16% of global maternal deaths in 2023.

What ProFound and the Gates Foundation Announced

The August 27, 2026 announcement separates the commitment into two pieces. ProFound has an initial $20M investment and a path to as much as $35M in total support. The companies did not disclose the legal instrument, valuation, ownership terms, or conditions governing the remaining $15M.

That distinction matters for both capital accounting and scientific expectations. Calling the announcement a $35M venture round would imply a structure the source does not provide. Treating the full commitment as already deployed would also outrun the evidence. The clean reading is that the Gates Foundation has committed up to $35M, beginning with $20M, for a focused global-health research program.

ProFound plans to examine novel proteins found in placenta and serum from women with preeclampsia and eclampsia. The program will use those samples to study causal biology, identify promising biomarkers and therapeutic targets, explore first-in-class protein drugs, and develop a disease-specific AI tool. No clinical candidate, validated diagnostic, trial, or regulatory plan was announced.

Why the Expanded Proteome Matters

ProFound was created at Flagship Labs in 2020 around a challenge to conventional genome annotation. Its founders believed that genomic regions labeled non-coding could still produce small, functional proteins that standard discovery systems had overlooked. The company says its work has identified tens of thousands of such proteins across human biology.

The ProFoundry Platform combines protein-detection technologies, high-throughput functional assays, computational methods, and the ProFoundry Atlas. Discovery is only the first layer. The platform is designed to test what a candidate protein does, how it connects to disease, and whether the evidence is strong enough to justify further development.

For preeclampsia, that creates a practical sequence. ProFound must find proteins present in relevant samples, establish reproducible associations, test causal relationships, and determine whether any candidate can become a useful biomarker, protein drug, or drug target. Its AI systems may prioritize hypotheses and connect evidence across the Atlas, but experimental validation remains the control point.

CEO and President John Lepore, MD, leads ProFound alongside a team that includes CTO Tom Chittenden, PhD, DPhil, PStat, DSPE and COO Ainslie Little, PhD. Chittenden oversees the ProFoundry Platform and its Atlas, placing the company’s computational and experimental systems under one technical mandate.

Why Preeclampsia Needs More Discovery Infrastructure

Preeclampsia is a hypertensive disorder that typically develops after 20 weeks of pregnancy. It can involve high blood pressure, protein in the urine, organ damage, placental complications, premature birth, fetal growth restriction, and maternal or fetal death. If it progresses to eclampsia, seizures can become life-threatening.

Existing care can prevent or manage part of that risk. WHO notes that magnesium sulfate can reduce the risk of eclampsia by more than half for women with preeclampsia. Low-dose aspirin, calcium supplementation in low-intake settings, blood-pressure management, and close antenatal monitoring also have defined roles. Access to those interventions remains uneven, particularly in low-resource health systems.

The discovery gap sits upstream of care delivery. Researchers still need better tools to identify who is at risk, distinguish disease pathways, validate biomarkers, and create new therapeutic options. A protein atlas becomes valuable when it narrows that uncertainty into evidence clinicians and product developers can use.

The Gates Foundation’s Women’s-Health Investment Logic

In 2025, the Gates Foundation committed $2.5B through 2030 to women’s-health research and development. The foundation cited a 2021 analysis finding that only about 1% of healthcare research and innovation spending went toward female-specific conditions outside oncology.

The ProFound commitment translates that broad funding thesis into a laboratory program. Instead of beginning with a late-stage product, the foundation is financing target and biomarker discovery in a disease that carries a large global burden. Herbert “Skip” Virgin, MD, PhD, Head of the foundation’s AI-Enabled Cures Frontier, described the goal as combining ProFound’s knowledge of the expanded proteome with agentic AI to generate biological insights for therapeutics and biomarkers.

The global-health test will arrive later. A target can be scientifically compelling and still fail to become an affordable diagnostic, accessible medicine, or deployable tool. The announcement does not yet identify sample partners, validation cohorts, product-access terms, clinical timelines, or delivery systems for countries where maternal mortality is highest.

What the Capital Must Prove Next

ProFound entered public view in 2022 with an initial $75M commitment from Flagship Pioneering. That historical commitment funded the broader ProFoundry platform and therapeutic pipeline. It should not be mechanically added to the new Gates Foundation commitment as a single “total raised” figure because both announcements use commitment language and disclose different structures.

The new capital is more focused. ProFound must move from a large field of possible proteins to a small set of reproducible findings tied to preeclampsia and eclampsia. It must show that its AI produces experimentally useful paths, that its biomarkers or targets survive representative validation, and that promising discoveries can move toward products intended for global access. That is the investment’s real shape: up to $35M to make hidden biology readable, followed by the harder work of proving that the reading can change what happens to mothers and babies.